Avid Bioservices Inc (CDMO)

[goodJohnhunting]

I think the 'IL' levels will do better because we know that there is a direct relation between IL-10/IL-12 changes when Bavituximab is in the mix. Patients with High IL-10 and/or Low IL-12 may benefit more from Bavi as bavi decreases IL-10 (the immuno suppression unblocking part) and increases IL-12 (the so needed immuno-activation part) which will result in immune system activation which in turn will lead to cell damage repair/evac, tumour fighting and adaptive immune system activity against relapse.

How can anything be confirmed as, "we know that there is a direct relation between IL-10/IL-12 changes when Bavituximab is in the mix", when the data mining proved that binding is unstable, unpredictable, and subject to unsubscribed variances?

Until these "unsubscribed variances" are known, and PK/PD is established, then all is noise, and the 2tonelephant lives on, IMO.

All the best,
John